Rare Diseases and Rare Cancers
.png)
Revolutionising Research for Rare Diseases, Transforming Lives
Empiric is paving the way for breakthrough treatments in rare diseases and rare cancers by leveraging adaptive platform trials and shared infrastructure. Our approach delivers faster, cost-effective trials that expand patient access to life-saving interventions while reducing barriers for pharmaceutical and biotech companies to achieve registration of novel therapeutics.
Smarter, Faster Evidence Generation
Empiric’s adaptive platform trials streamline research for rare diseases, allowing multiple treatments to be tested simultaneously under shared infrastructure. This reduces costs and accelerates timelines by up to 50%.
Enhanced Patient Access and Experience
Patients benefit from increased access to trials designed with their needs in mind. Features such as shared control arms, tiered levels of participation and response-adaptive randomisation are better for participants. At Empiric, we believe individuals with lived experience have the right to shape what is researched and how it is conducted, benefiting both patients and companies developing innovative products.
.png)
Empowering Collaboration and Innovation
Empiric brings together pharmaceutical companies, health service organisations, and rare disease patient groups to create a unified platform that creates a new model of care in which the trial is the treatment. Companies retain control over proprietary data while benefiting from lower costs and faster market entry for their treatments.
.png)
.png)
